Background. Based on previous pharmacokinetic and pharmacodynamic studies, we have developed an EEG-controlled closed-loop system for the i.v. hypnotic agent propofol in rats.
Feedback models are also powerful devices in pharmacological studies and for the assessment of drug±drug interactions. In circumstances where clinical or ethical problems occur in volunteer or patient studies, feedbackcontrolled animal models might at least indicate a trend for the type of interaction in humans and can lead to a distinct reduction in the number of animals needed to obtain signi®cant results. The aim of this study was to establish an EEG-controlled closed-loop system for the i.v. hypnotic agent propofol in rats, based on previous pharmacokinetic and pharmacodynamic ®ndings. 3 
Methods
Animals quarantine and acclimatization. Animals were healthy with respect to serology, bacteriology, parasitology and pathology. The rats were housed in pairs in polycarbonate cages type III (Uno BV, the Netherlands) on standard research bedding (soft wood ®bre, Altromin) at 21.0 (0.5)°C, 60% humidity, 12 h light/dark cycle, with pelleted standard rodent diet (No. 1320, Altromin) and tap water ad libitum.
Instrumentation
For instrumentation, animals were anaesthetized with ketamine (Ketavetâ 100 mg ml ±1 , Pharmacia, Germany) 158 (19) mg kg ±1 i.p. This dose ensured adequate anaesthesia and analgesia for at least 60 min without any reaction to surgical procedures. Incision sites were in®ltrated with lidocaine 2%. The right jugular vein and the left femoral artery were cannulated for administration of propofol 10 mg ml ±1 (Diprivanâ, AstraZeneca, Germany) and blood gas analysis, respectively. Stainless steel EEG needle electrodes were placed occipito±occipitally. The trachea was intubated for arti®cial ventilation to maintain stable blood gas status. During arti®cial ventilation the rats were paralysed with repetitive doses of pancuronium. Temperature was maintained at 36.5 (0.5)°C with a heating pad. Arterial pressure was measured continuously via the arterial cannula.
EEG processing and pharmacodynamic analysis
One-channel EEG was continuously recorded with an Aspect A1000 monitor (Aspect medical systemsÔ, Natick, MA, USA). The digitized EEG signal was processed online with internal EEG analysis software (sampling rate 128 Hz, epoch length 8 s) and the median frequency (MEF) of the power spectrum (0.5±32 Hz) was determined using a fast Fourier transformation. In previous studies 3 4 we found that the EEG of rats under propofol anaesthesia shows burst suppressions (BS) and spike-like patterns with high frequency components so that the MEF ®rst decreases with increasing propofol concentration and then paradoxically increases. We therefore introduced a modi®ed MEF (mMEF), which decreases continuously with increasing propofol concentration; this mMEF was also used in the present study. The mMEF algorithm uses pattern recognition to identify spikes and modi®es the MEF in a manner similar to that which has been used for BS. 3 5 
Drug administration
When the mMEF was at least 8 Hz, propofol administration was started, targeting constant propofol blood concentrations by means of a pharmacokinetic model (targetcontrolled infusion, TCI; see Appendix). As an EEG set point we chose an mMEF of 3 (0.5) Hz, based on previous experience with propofol. At this level, we have a relatively deep anaesthesia, the EEG is characterized by spike-like patterns but the incidence of BS is low and the propofolinduced arterial pressure decrease is not too profound. As the mMEF can further decrease until a minimum value of 0 Hz, which will be reached if the EEG is completely suppressed, a set point of 3 Hz will avoid the ceiling effect where the mMEF is virtually independent of drug concentration. When mMEF was close to the chosen EEG set point of 3 (0.5) Hz, the EEG-controlled closed-loop administration (feedback mode) was started and maintained for 90 min. Propofol infusion was controlled by a modelbased adaptive control algorithm, as explained in detail in the Appendix.
Analysis of the EEG and control of the propofol infusion were performed on a notebook computer with software written by the authors. Infusion rates, cumulative doses and derived EEG parameters were stored on disk for further investigation. The effective therapeutic infusion rate (ETI), as proposed some time ago by Schwilden and colleagues, 6 was calculated as the slope of the cumulative dose curves during closed-loop controlled infusion for each individual animal. A normal distribution function was ®tted to the distribution of the individual ETI values, and the 50%, 75% and 95% points (ED 50 , ED 75 , ED 95 respectively) as well as the interquartile range (ED 25 ±ED 75 ) were determined from the ®tted function. To provide arousal stimuli and avoid natural sleep during feedback-controlled drug administration, rats received nociceptive stimuli (tail squeeze) which were randomized with respect to time and intensity.
Assessment of the performance of the feedback system
The feedback system was characterized by several performance measures as proposed by Varvel and colleagues. 7 The performance error (PE) was determined as relative deviation from the set point: EEG closed-loop control in rats
where mMEF ij is the jth measured mMEF in the ith animal.
As a quantitative measure of bias we determined in each animal the median PE:
and as a quantitative measure of inaccuracy the median absolute PE:
whereby N i is the number of performance errors in the ith animal. Furthermore, we performed in each animal a linear regression of |PE ij | versus time and de®ned the divergence D i as the slope of the regression line, which is a measure for a time-related trend of the performance. The wobble W i =median {|PE ij ± MDPE i |, j =1,...N i } was calculated for each animal as a measure for the intra-individual variability of the PE. The performance in the population was characterized by the unweighted mean of MDPE i , MDAPE i , D i and W i and SEM, as de®ned by Varvel and colleagues. 7 All other data are presented as mean (SD), unless stated.
Results
Propofol administration was started 107 (34) min after ketamine. User-de®ned targets of propofol concentration (TCI mode) to get close to the chosen EEG set point of 3.0 (0.5) Hz were 5.6 (1.6) mg ml ±1 . Feedback-controlled infusion was started 35 (23) min after the start of TCI. In all rats a feedback period of 90 min could be performed. Figure 2 shows the time course of the performance quality for each animal, expressed as mMEF/set point. MDPE and MDAPE were 1.2 (SE 0.4)% and 13.9 (0.3)%, respectively, divergence was ±3.5 (0.5)% h ±1 and wobble was 13.4 (0.3)%. The mean mMEF for all animals during closed-loop infusion was 3.0 (0.7) Hz. Figure 3 shows the worst and the best case of the study, as indicated by the values of MDPE and MDAPE. Cumulative doses increased linearly and were 46 (11) mg in total and 36 (14) mg during closed-loop infusion (Fig. 4) . The ETI rate was 0.73 (0.20) mg kg ±1 min ±1 . Figure 5 shows the distribution of the ETI values to achieve the set point of 3.0 (0.5) Hz. From the probability curve, ED 50 , ED 75 and ED 95 were determined to be 0.73, 0.87 and 1.07 mg kg ±1 min ±1 , respectively. The interquartile range ED 25 ±ED 75 was 0.60±0.87 mg kg ±1 min ±1 . As described previously, EEG spike patterns were observed shortly after the start of the target-controlled propofol administration and before the occurrence of EEG BS (Fig. 6) . The BS ratio (BSR), de®ned as the fraction of the EEG epoch where the EEG is suppressed, was 6.1 (5.7)% for all animals. The number of spikes increased with increasing propofol concentrations.
Mean arterial pressure (MAP) before the start of propofol infusion was 148 (14) mm Hg and lowest MAP during closed-loop infusion was 110 (20) mm Hg. After stopping the closed-loop infusion MAP reached baseline values within 3±5 min. 
Discussion
We have developed a system for EEG-controlled feedback administration of propofol in rats as a research tool for pharmacokinetic/dynamic studies. In a traditional pharmacological approach, the dose is manually adjusted and the resulting effect is observed. With feedback systems, a de®ned pharmacodynamic effect is set and the dose necessary to achieve and maintain this effect will be found by the control algorithm. One application for a feedback-controlled dosage system is the speedy determination of dose requirements from which the ED 50 or higher values such as ED 75 or ED 95 , which have more practical relevance, can be determined easily (Fig. 5) . Furthermore, feedback systems are useful devices not only to accelerate the testing of new drugs, but also for the evaluation of interactions. Drug±drug interactions are usually investigated by the construction of isoeffective curves (isoboles) on a graph with concentrations or infusion rates of drug A and drug B on the axes. A common problem with this method is the assessment of the end-points of the isobole. 8 In volunteer or patient studies there are often ethical or clinical problems in studying isoeffective drug combinations with very low concentrations or infusion rates of one drug. These end-points could easily be assessed in animal models and the resulting isobole could at least indicate a trend for the type of interaction in humans. Usually, isoeffective drug combinations are found by manual adjustment of drug dosing to maintain the desired effect. With a feedback system, one can choose different doses of drug A and the feedback system will then automatically adjust the infusion rate of drug B to achieve the pharmacodynamic set point. This approach will accelerate the evaluation of drug±drug interactions and can help to reduce the number of animals used.
However, a condition precedent for a functioning feedback device is that a drug effect can be measured continuously and reliably, as this effect serves as an input for the control algorithm. As characteristic patterns occurred in the rat EEG with increasing propofol concentrations, we could not use`standard' EEG parameters for feedback control, for example spectral edge frequency or MEF. The high-frequency components of these patterns make such simple EEG parameters unsuitable for closed-loop control. Therefore, mMEF, which revealed a good correlation with hypnotic drug concentrations in previous studies 3 4 served as an input for our closed-loop system.
There are only a few publications regarding automatic drug control of anaesthetics in rats. Angel and colleagues 9 have described a system that uses somatosensory evoked potentials (SSEP) for closed-loop control of propofol in rats. The mean PE in their experiments ranged from 3.8 to 90.5%. However, as SSEP show large spontaneous¯uctu-ations in responsiveness, this PE cannot be directly compared with the PE in our study. Vijn and colleagues 2 have published a feedback system to maintain different BSR with propofol and etomidate in rats for 60 min. BSRs maintained in their study were 30, 50, 70 and 90%. They assessed the performance of their feedback system by the SD of the BSR distribution around the BSR target during the 10±50 min time interval. In their experiments, SD never exceeded 5%, which seems to be a better performance than we achieved (MDAPE=13.9%). However, as their performance parameter is not directly comparable with the parameters for performance assessment used in our study, one can only roughly compare the performances of the two systems. Another problem is that EEG parameters show large statistical noise and thus an averaging process is necessary. This averaging process strongly affects the smoothness of the time curves of the measured effects and thereby the PE. In addition, when comparing different closed-loop systems, one has to consider the different set points. We tried to stabilize the pharmacodynamic effect on the steep part of the concentration±effect curve, whereas Vijn and colleagues maintained different BSR, which might indicate ceiling effects. Therefore, in our system small changes in propofol concentrations led to relatively large changes in the observed pharmacodynamic effect and thus to a relatively poorer performance. Another point when choosing the appropriate set point is that if one intends to establish a feedback device for preclinical evaluation of drug±drug interactions, BSR as a pharmacodynamic end-point might be too high to assess relevant effects of a second hypnotic drug. Whereas BS indicate deep or very deep states of general anaesthesia, it may be bene®cial to target a pharmacodynamic parameter that is measurable and reliable over the whole range from light sedation to deep general anaesthesia.
Using the feedback system, the ETI rate in our study was 0.73 (0.20) mg kg ±1 min ±1 . This is comparable to the rate of 0.64 (0.03) mg kg ±1 min ±1 found by Vijn and colleagues 2 to maintain 30% BSR. For maintaining a BSR of 90%, they found a mean infusion rate of 1.70 (0.05) mg kg ±1 min ±1 . In a study of Akrawi and colleagues, 10 anaesthetic drug infusion was manually adjusted to maintain a state in which suppressions were present 80% of the time. Mean infusion rates of propofol to maintain this effect were reported to be 1.6±2.0 mg kg ±1 h ±1 , which is approximately 60-fold less than in our study and that of Vijn and colleagues. It is unlikely that these large differences are caused by differences in animals with respect to strain and age (Vijn and colleagues used Wistar rats weighing 220±300 g; Akrawi and colleagues used Sprague±Dawley rats weighing 375±450 g) or by differences in BS detection. Nevertheless, one needs to consider that different methods for detection of BS might in¯uence the derived pharmacodynamic parameters and thereby the resulting infusion rates.
In conclusion, the closed-loop device presented here seems to be a promising research tool with reasonable performance to conduct pharmacological studies such as determination of dose requirements or drug±drug-interactions at preset levels of effect.
Appendix: Feedback system
Propofol infusion was controlled by a model-based adaptive control algorithm to maintain a chosen set point. 11 The feedback system combined a pharmacokinetic and a pharmacodynamic model based on a previous study 3 to relate the dose with effect. The pharmacokinetic model was a one-compartment model with a central volume of distribution (Vc) of 0.68 litres and a clearance (CL) of 45 ml min ±1 . An additional effect compartment (biophase) was assumed as a site of drug action to assess the delay between propofol plasma concentration and effect (hysteresis). 12 The equilibration between plasma concentration and effect-site concentration (c E ) was characterized by the rate constant k e0 =0.4 min ±1 . In this model, the plasma concentration after a bolus dose D is c(t) = A´e ±a´t and the corresponding c E is with the mMEF as pharmacodynamic effect E and the following parameters: baseline effect E 0 =10 Hz, concentration at half maximum effect EC 50 =4 mg ml ±1 and Hill coef®cient g=2.5.
Based on the pharmacokinetic model, the controller determined the propofol infusion rate to achieve a de®ned propofol concentration (target). This target concentration could either be set by the user (TCI mode) or it was automatically adjusted by the feedback algorithm (closedloop control mode). If the measured effect E(c 1 ) at the target concentration c 1 was different from the set point, a new target concentration c 2 was de®ned. For this purpose we applied a ®rst-order Taylor series approximation of the concentration±effect relationship about the concentration c 1 :
where dE/dc is the ®rst derivative of the Hill function at concentration c 1 . From this equation, a new target concentration c 2 was obtained as: where DE was the average deviation of the mMEF from the set point during the last 20 epochs. To avoid overshooting, the maximum increase of the target was limited to 10% of the current target, and a new target was not set until the calculated effect-site concentration had approximated the current target (difference less than 10%). The target was not changed if abs(DE) was less than 0.25 Hz.
To adapt the pharmacokinetic/dynamic model to the individual animal, the controller performed an online analysis of the measured effect (mMEF). For a number of Np epochs, the hypothetical effect-site concentrations were calculated from the measured effects by inverting the Hill equation:
From the known infusion rates, the ratio A/EC 50 for the individual animal was determined online, where A is the coef®cient of the pharmacokinetic disposition function. If no measured concentrations are available, one cannot determine both A and EC 50 from the measured effect but only the ratio A/EC 50 . 13 If, for example, the effect is greater than predicted by the default model, this can be caused by a higher coef®cient A and, consequently, a higher concentration than predicted, or it can be caused by a decreased EC 50 (i.e. a greater sensitivity to the drug). The parameter adaptation was performed for the ®rst time 10 min after the start of closed-loop control and subsequently at intervals of 5 min. The number Np of analysed epochs was equal to the total number of elapsed epochs (Ne) if Ne`200, and was Np=200 if Ne>200.
